nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.09.2014 | NON-THEMATIC REVIEW

Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses

verfasst von: Masahisa Jinushi

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2014

Einloggen, um Zugang zu erhalten

Abstract

Emerging evidence has unveiled a critical role for immunological parameters in predicting tumor prognosis and clinical responses to anticancer therapeutics. On the other hand, responsiveness to anticancer drugs greatly modifies the repertoires, phenotypes, and immunogenicity of tumor-infiltrating immune cells, serving as a critical factor to regulate tumorigenic activities and the emergence of therapy-resistant phenotypes. Tumor-associated immune functions are influenced by distinct or overlapping sets of therapeutic modalities, such as cytotoxic chemotherapy, radiotherapy, or molecular-targeted therapy, and various anticancer modalities have unique properties to influence the mode of cross-talk between tumor cells and immune cells in tumor microenvironments. Thus, it is critical to understand precise molecular machineries whereby each anticancer strategy has a distinct or overlapping role in regulating the dynamism of reciprocal communication between tumor and immune cells in tumor microenvironments. Such an understanding will open new therapeutic opportunities by harnessing the immune system to overcome resistance to conventional anticancer drugs.

Higgins, C. F. (2007). Multiple molecular mechanisms for multidrug resistance transporters. Nature, 446, 749–757.PubMedCrossRef

Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105–111.PubMedCrossRef

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 141, 69–80.PubMedCrossRefPubMedCentral

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer, 13, 714–726.PubMedCrossRef

Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 141, 583–594.PubMedCrossRefPubMedCentral

Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell, 23, 811–825.PubMedCrossRef

Magee, J. A., Piskounova, E., & Morrison, S. J. (2012). Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 21, 283–296.PubMedCrossRef

Clevers, H. (2011). The cancer stem cell: premises, promises and challenges. Nature Medicine, 17, 313–319.PubMedCrossRef

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., et al. (2005). Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 70, 419–426.PubMedCrossRef

10.

Poulikakos, P. I., & Rosen, N. (2011). Mutant BRAF melanomas—dependence and resistance. Cancer Cell, 19(1), 11–15.PubMedCrossRef

11.

Nahta, R., Yu, D., Hung, M. C., Hortobagyi, G. N., & Esteva, F. J. (2006). Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice Oncology, 3(5), 269–280.PubMedCrossRef

12.

Gilbert, L. A., & Hemann, M. T. (2010). DNA damage-mediated induction of a chemoresistant niche. Cell, 143, 355–366.PubMedCrossRefPubMedCentral

13.

Pallasch, C. P., Leskov, I., Braun, C. J., Vorholt, D., Drake, A., & Soto-Feliciano, Y. M. (2014). Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell, 156(3), 590–602.PubMedCrossRef

14.

Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V., et al. (2009). A stroma-related signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 15, 68–74.PubMedCrossRef

15.

Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2010). An epigenetic switch involving NF-kB, Lin28, Let-7 MicroRNA, and IL-6 links inflammation to cell transformation. Cell, 139, 693–706.CrossRef

16.

Gilvennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140, 883–899.CrossRef

17.

Lake, R. A., & Robinson, B. W. (2005). Immunotherapy and chemotherapy—a practical partnership. Nature Reviews Cancer, 5(5), 397–405.PubMedCrossRef

18.

Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013). Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity, 39, 74–88.PubMedCrossRef

19.

Jinushi, M., Yagita, H., Yoshiyama, H., & Tahara, H. (2013). Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells. Trends in Molecular Medicine, 9, 536–545.CrossRef

20.

Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., et al. (2013). Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nature Medicine, 19(1), 57–64.PubMedCrossRef

21.

Huang, B., Zhao, J., Li, H., He, K. L., Chen, Y., & Chen, S. H. (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Research, 65(12), 5009–5014.PubMedCrossRef

22.

Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008). TLR signaling by tumor and immune cells: a double-edged sword. Oncogene, 27(2), 218–224.PubMedCrossRef

23.

Dranoff, G. (2004). Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews Cancer, 4, 11–22.PubMedCrossRef

24.

Lin, W. W., & Karin, M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation, 117, 1175–1183.PubMedCrossRefPubMedCentral

25.

Tye, H., Kennedy, C. L., Najdovska, M., McLeod, L., McCormack, W., Hughes, N., et al. (2012). STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell, 22(4), 466–478.PubMedCrossRef

26.

Huang, B., Zhao, J., Shen, S., Li, H., He, K. L., Shen, G. X., et al. (2007). Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Research, 67(9), 4346–4352.PubMedCrossRef

27.

Szajnik, M., Szczepanski, M. J., Czystowska, M., Elishaev, E., Mandapathil, M., Nowak-Markwitz, E., et al. (2009). TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene, 28, 4353–4563.PubMedCrossRefPubMedCentral

28.

Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., et al. (2010). Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. Journal of Clinical Investigation, 120, 1285–1297.PubMedCrossRefPubMedCentral

29.

Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., et al. (2012). Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nature Immunology, 13, 832–842.PubMedCrossRefPubMedCentral

30.

Tang, D., & Lotze, M. T. (2012). Tumor immunity times out: TIM-3 and HMGB1. Nature Immunology, 9, 808–810.CrossRef

31.

Green, D. R., et al. (2009). Immunogenic and tolerogenic cell death. Nature Reviews Immunology, 9, 353–363.PubMedCrossRefPubMedCentral

32.

Obeid, M., et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nature Medicine, 13, 54–61.PubMedCrossRef

33.

Jinushi, M., et al. (2009). Milk fat globule EGF-8 triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. Journal of Experimental Medicine, 206, 1317–1326.PubMedCrossRefPubMedCentral

34.

Loges, S., Schmidt, T., Tjwa, M., van Geyte, K., Lievens, D., Lutgens, E., et al. (2010). Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood, 115(11), 2264–2273.PubMedCrossRef

35.

Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., et al. (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature, 461(7261), 282–286.PubMedCrossRefPubMedCentral

36.

Chao, M. P., Majeti, R., & Weissman, I. L. (2011). Programmed cell removal: a new obstacle in the road to developing cancer. Nature Reviews Cancer, 12, 58–67.PubMed

37.

Chao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., et al. (2010). Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and counterbalanced by CD47. Science Translational Medicine, 2(63), 63ra94.PubMedCrossRef

38.

Jaiswal, S., Jamieson, C. H., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell, 138(2), 271–285.PubMedCrossRefPubMedCentral

39.

Baghdadi, M., Yoneda, A., Yamashina, T., Nagao, H., Komohara, Y., Nagai, S., et al. (2013). TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity, 39, 1070–1081.PubMedCrossRef

40.

Jinushi, M., Chiba, S., Baghdadi, M., Kinoshita, I., Dosaka-Akita, H., Ito, K., et al. (2012). ATM-mediated DNA damage signals mediate immune escape through integrin-αvβ3-dependent mechanisms. Cancer Research, 72(1), 56–65.PubMedCrossRef

41.

Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., et al. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 444, 638–642.PubMedCrossRef

42.

Mooi, W. J., & Peeper, D. S. (2006). Oncogene-induced cell senescence—halting on the road to cancer. New England Journal of Medicine, 355, 1037–1046.PubMedCrossRef

43.

Collado, M., Blasco, M. A., & Serrano, M. (2007). Cellular senescence in cancer and aging. Cell, 130, 223–233.PubMedCrossRef

44.

Kuilman, T., & Peeper, D. S. (2009). Senescence-messaging secretome: SMS-ing cellular stress. Nature Reviews Cancer, 9(2), 81–94.PubMedCrossRef

45.

Coppé, J. P., Desprez, P. Y., Krtolica, A., & Campisi, J. (2010). The senescence-associated secretory phenotype: the dark side of tumor suppression. Annual Review of Pathology, 5, 99–118.PubMedCrossRef

46.

Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., & Morton, J. P. (2013). A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature Cell Biology, 8, 978–990.CrossRef

47.

Kuilman, T., Michaloglou, C., Vredeveld, L. C., Douma, S., van Doorn, R., Desmet, C. J., et al. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 133(6), 1019–1031.PubMedCrossRef

48.

Pazolli, E., Alspach, E., Milczarek, A., Prior, J., Piwnica-Worms, D., & Stewart, S. A. (2012). Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Research, 72(9), 225122–225161.CrossRef

49.

Canino, C., Mori, F., Cambria, A., Diamantini, A., Germoni, S., Alessandrini, G., et al. (2012). SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene, 31(26), 3148–3163.PubMedCrossRef

50.

Yoshimoto, S., Loo, T. M., Atarashi, K., Kanda, H., Sato, S., Oyadomari, S., et al. (2013). Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 499, 97–101.PubMedCrossRef

51.

Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., & Bolden, J. E. (2013). Non-cell-autonomous tumor suppression by p53. Cell, 153, 449–460.PubMedCrossRefPubMedCentral

52.

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., et al. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445(7128), 656–660.PubMedCrossRef

53.

Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., et al. (2012). Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes and Development, 25(20), 2125–2136.CrossRef

54.

Formenti, S. C., & Demaria, S. (2009). Systemic effects of local radiotherapy. Lancet Oncology, 10(7), 718–726.PubMedCrossRefPubMedCentral

55.

Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., et al. (2013). Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell, 24(5), 589–602.PubMedCrossRef

56.

Burnette, B. C., Liang, H., Lee, Y., Chlewicki, L., Khodarev, N. N., Weichselbaum, R. R., et al. (2011). The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Research, 71(7), 2488–2496.PubMedCrossRefPubMedCentral

57.

Lee, Y., Auh, S. L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., et al. (2009). Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood, 114(3), 589–595.PubMedCrossRefPubMedCentral

58.

Takeshima, T., Chamoto, K., Wakita, D., Ohkuri, T., Togashi, Y., Shirato, H., et al. (2010). Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Research, 70(7), 2697–2706.PubMedCrossRef

59.

Ludgate, C. M. (2012). Optimizing cancer treatments to induce an acute immune response: radiation Abscopal effects, PAMPs, and DAMPs. Clinical Cancer Research, 18, 4522–4525.PubMedCrossRef

60.

Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., et al. (2007). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunology Reviews, 220, 47–59.CrossRef

61.

Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nature Reviews Cancer, 12, 860–875.PubMedCrossRef

62.

Kozin, S. V., Duda, D. G., Munn, L. L., & Jain, R. K. (2012). Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? Journal of the National Cancer Institute, 104, 899–905.PubMedCrossRefPubMedCentral

63.

Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S., West, B., et al. (2013). CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Research, 73(9), 2782–2794.PubMedCrossRefPubMedCentral

64.

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 7(3), 169–181.PubMedCrossRef

65.

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129–2139.PubMedCrossRef

66.

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 352(8), 786–792.PubMedCrossRef

67.

Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., et al. (2011). FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature, 47, 523–526.CrossRef

68.

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039–1043.PubMedCrossRef

69.

Vanneman, M., & Dranoff, G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 12(4), 237–251.PubMedCrossRefPubMedCentral

70.

Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., et al. (2007). Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. Journal of Clinical Investigation, 117, 3846–3856.PubMedCrossRefPubMedCentral

71.

Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., et al. (2011). Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 108(30), 12425–12430.PubMedCrossRefPubMedCentral

72.

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., et al. (2012). Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics, 44(8), 852–860.PubMedCrossRefPubMedCentral

73.

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., BRIM-3 Study Group, et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364, 2507–2516.PubMedCrossRefPubMedCentral

74.

Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006). The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. Journal of Experimental Medicine, 203, 1651–1656.PubMedCrossRefPubMedCentral

75.

Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013). The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clinical Cancer Research, 19, 598–609.PubMedCrossRef

76.

Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., et al. (2013). Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. Journal of Clinical Investigation, 123, 1371–1381.PubMedCrossRefPubMedCentral

77.

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., et al. (2013). BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Research, 19, 1225–1231.PubMedCrossRefPubMedCentral

78.

Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Global ARCC Trial, et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356, 2271–2281.PubMedCrossRef

79.

Pearce, E. L., & Pearce, E. J. (2013). Metabolic pathways in immune cell activation and quiescence. Immunity, 38, 633–643.PubMedCrossRefPubMedCentral

80.

Waickman, A. T., & Powell, J. D. (2012). mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunology Reviews, 49, 43–58.CrossRef

81.

Amiel, E., Everts, B., Freitas, T. C., King, I. L., Curtis, J. D., Pearce, E. L., et al. (2012). Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. Journal of Immunology, 189, 2151–2158.CrossRef

82.

Berezhnoy, A., Castro, I., Levay, A., Malek, T. R., & Gilboa, E. (2014). Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. Journal of Clinical Investigation, 124, 188–197.PubMedCrossRefPubMedCentral

83.

Bianchini, G., & Gianni, L. (2014). The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncology, 2, e58–e68.CrossRef

84.

Taylor, C., Hershman, D., Shah, N., Suciu-Foca, N., Petrylak, D. P., Taub, R., et al. (2007). Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clinical Cancer Research, 13, 5133–5143.PubMedCrossRef

85.

DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., et al. (2011). Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discovery, 1(1), 54–67.PubMedCrossRefPubMedCentral

86.

Kohrt, H. E., Nouri, N., Nowels, K., Johnson, D., Holmes, S., & Lee, P. P. (2005). Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Medicine, 2(9), e284.PubMedCrossRefPubMedCentral

87.

Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007). Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer, 8, 585–598.CrossRef

88.

Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators, et al. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487–2498.PubMedCrossRef

89.

Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., MM-015 Investigators, et al. (2012). Continuous lenalidomide treatment for newly diagnosed multiple myeloma. New England Journal of Medicine, 366, 1759–1769.PubMedCrossRef

90.

Chauhan, D., Singh, A. V., Brahmandam, M., Carrasco, R., Bandi, M., Hideshima, T., et al. (2009). Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell, 16, 309–323.PubMedCrossRefPubMedCentral

91.

Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y. T., Prabhala, R. H., Ritz, J., et al. (2008). MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 105, 1285–1290.PubMedCrossRefPubMedCentral

92.

Martiniani, R., Di Loreto, V., Di Sano, C., Lombardo, A., & Liberati, A. M. (2012). Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Advances in Hematology, 2012, 842945.PubMedCrossRefPubMedCentral

93.

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., et al. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nature Medicine, 15, 1170–1178.PubMedCrossRef

94.

Yamamoto, R., Nishikori, M., Tashima, M., Sakai, T., Ichinohe, T., Takaori-Kondo, A., et al. (2009). B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Science, 100, 2093–2100.PubMedCrossRef

95.

Ribas, A., & Wolchok, J. D. (2013). Combining cancer immunotherapy and targeted therapy. Current Opinion in Immunology, 25, 291–296.PubMedCrossRefPubMedCentral

Titel: Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses
verfasst von: Masahisa Jinushi
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2-3/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9501-9

Springer Medizin

Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2014

Integrating new discoveries into the “vicious cycle” paradigm of prostate to bone metastases

Immunotherapy for prostate cancer: recent developments and future challenges

Emerging strategies to overcome resistance to endocrine therapy for breast cancer

Clinical models and biochemical predictors of VTE in lung cancer

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance

Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie